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Introduction: Chronic neuropathic low back pain (CNLBP) is a debilitating condition in which established medical
treatments seldom alleviate symptoms. Evidence demonstrates that high-frequency 10 kHz spinal cord stimulation
(SCS) reduces pain and improves health-related quality of life in patients with failed back surgery syndrome (FBSS),
but evidence of this effect is limited in individuals with CNLBP who have not had surgery. The aim of this
multicentre randomised trial is to assess the clinical and cost-effectiveness of 10 kHz SCS for this population.
Methods: This is a multicentre, double-blind, randomised, sham-controlled trial with a parallel economic evaluation.
A total of 96 patients with CNLBP who have not had spinal surgery will be implanted with an epidural lead and a
sham lead outside the epidural space without a screening trial. Patients will be randomised 1:1 to 10 kHz SCS plus
usual care (intervention group) or to sham 10 kHz SCS plus usual care (control group) after receiving the full
implant. The SCS devices will be programmed identically using a cathodal cascade. Participants will use their
handheld programmer to alter the intensity of the stimulation as per routine practice. The primary outcome will be
a 7-day daily pain diary. Secondary outcomes include the Oswestry Disability Index, complications, EQ-5D-5 L, and
health and social care costs. Outcomes will be assessed at baseline (pre-randomisation) and at 1 month, 3 months
and 6 months after device activation. The primary analyses will compare primary and secondary outcomes between
groups at 6 months, while adjusting for baseline outcome scores. Incremental cost per quality-adjusted life year
(QALY) will be calculated at 6 months and over the lifetime of the patient.
Discussion: The outcomes of this trial will inform clinical practice and healthcare policy on the role of high-frequency
10 kHz SCS for use in patients with CNLBP who have not had surgery.
Trial registration: Clinicaltrials.gov, NCT03470766. Registered on 20 March 2018.
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The prevalence of chronic low back pain in adults world-
wide is estimated to range from 12 to 28% [1–4]. This leads
to prolonged disability and time lost from work for those
affected [5]. Within this group, an estimated 12–15% suffer
from chronic neuropathic lower back pain (CNLBP), have
relatively greater pain severity and account for more of the
costs of this condition [6, 7]. Neuropathic pain is defined as
a lesion or disease of the somatosensory system. Commonly
used therapies for low back pain are largely ineffective for
CNLBP [8].
The National Institute for Health and Care Excel-
lence (NICE) recommends spinal cord stimulation
(SCS) for refractory neuropathic pain. SCS is rou-
tinely used for people with predominantly neuropathic
radicular pain that typically results from, or persists
after, spinal surgery (so-called failed back surgery syn-
drome [FBSS]) [9, 10]. SCS has demonstrated cost ef-
fectiveness for this indication [11]. However, because
of a lack of existing evidence and the difficulty in
obtaining paraesthesia over the lower back, SCS has
not been commonly used for treating patients with
back pain who have not had spinal surgery [10, 12].
High-frequency 10 kHz SCS (Nevro, Redwood, CA,
USA) is a recent advance in SCS technology. The
current is delivered at a frequency of 10 kHz, as opposed
to the 40 to 60 Hz generated by conventional SCS [13].
The key advantage of a higher frequency current is its
apparent superiority to conventional SCS in targeting re-
sidual low back pain following back surgery [14]. More-
over, it does not generate any stimulation-related
sensations, known as ‘paraesthesias’ that can become in-
tolerable [14, 15]. An advantage in this absence of par-
aesthesia is that 10 kHz SCS provides the opportunity
for sham-controlled and double-blind studies in the field
of SCS, without the need for device modifications.
Our group has conducted an uncontrolled, multicen-
tre, single-arm study in which 72 patients with signifi-
cant low back pain with or without leg pain were
implanted with a 10 kHz SCS [16]. This was a mixed co-
hort of patients with and without prior spinal surgery.
At 24 months, the mean reported visual analogue scale
(VAS) score for back pain was 3.3 (SD 0.3) in 65 pa-
tients, compared with 8.4 (SD 0.1) at baseline (pre-im-
plant) and 2.7 (SD 0.3) at 6 months [16]. A total of 60%of all patients were responders (> 50% reduction in back
pain) at 24 months [16]. VAS is a psychometric response
scale used to measure pain severity between 0 and 10
cm, with 10 cm indicating the worst imaginable pain ex-
perienced [17]. Similar improvements were observed in
leg pain, disability and sleep, with marked reductions in
medication intake [16].
In a more recent multicentre randomised controlled
trial (RCT), 10 kHz SCS therapy demonstrated superior-
ity to conventional tonic SCS in the treatment of FBSS.
A total of 198 participants with both back and leg pain
were randomised to 10 KHz SCS or conventional SCS.
The 10 kHz SCS decreased the back pain intensity by
67% compared to 44% in the conventional SCS arm [18].
This decrease was sustained at 24 months [19].
The above-mentioned studies focused on neuropathic
back pain in the context of patients with previous spinal
surgery. However, a small subset of patients who had
not received spine surgery and had received 10 kHz SCS
therapy in these studies also experienced pain relief and
functional improvements comparable to those of pa-
tients with FBSS [14, 18].
We hypothesised that patients with CNLBP who had
no prior spine surgery would benefit from 10 kHz SCS.
To evaluate this hypothesis, we initially designed and
conducted an open-label, uncontrolled, pilot study in 21
patients with CNLBP and no prior spine surgery. The
10 kHz SCS therapy significantly reduced the VAS for
back pain intensity by a mean of 5.59 (SD 1.80) at 12
months in patients with medically refractory low back
and with no past history of spine surgery. Of the im-
planted patients, 90% were classified as responders (i.e.
VAS back pain reduction > 50%) at 12 months. We also
observed a significant increase in the physical function
scores and health-related quality of life at one year post-
10 kHz SCS implantation. The mean pain intensity was
reduced by 73%, and the disability measured by the
Oswestry Disability Index (ODI) was reduced by 48%.
Opioid medication intake decreased by 64%, and the
mean EQ-5D quality of life scores improved from 0.16
to 0.47. Remarkably, 75% of patients were able to return
to employment [20]. This improvement was sustained
through the 3-year follow-up [21].
To date 10 kHz SCS has not been formally tested
against a sham therapy, which is needed to isolate the
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cebo [22]. Possibly, some of the benefits reported may
be nonspecific treatment effects (enhanced by a surgical
procedure) or result from reporting bias in either the pa-
tient or assessor [22]. We have therefore specifically de-
signed this fully powered, double-blind, randomised,
sham-controlled trial of 10 kHz SCS to address this
major methodological limitation of previous studies.
Objectives
Hypothesis: The addition of 10 kHz SCS to usual med-
ical care (intervention group) will provide superior back
pain relief, compared to sham stimulation plus usual
medical care (control group) for CNLBP.
Aim: The overarching aim of this study is to demon-
strate the efficacy, safety and cost-effectiveness of 10
kHz SCS in the treatment of CNLBP with no prior
surgery.
Trial Design
This is a multicentre, randomised, double-blind, superiority,
sham-controlled trial with parallel economic evaluation.Fig. 1 Consort diagram of MODULATE-LBP trialPatients will be individually allocated to activated 10 kHz
SCS plus usual care (intervention) or sham 10 kHz SCS plus
usual care (control) and followed up for 6months. A sum-
mary of the study CONSORT diagram is illustrated in Fig. 1.
Methods
This protocol has been prepared and reported in accord-
ance with the Defining Standard Protocol Items for Clin-
ical Trials (SPIRIT) statement (Additional file 2) [23].
Study Setting
Participants will be recruited from two neuromodulation
centres: Guy’s & St. Thomas NHS Foundation Trust,
London, UK, and South Tees Hospitals NHS Foundation
Trust, Middlesbrough, UK.
Patient and Public Involvement
We organised three Patient and Public Involvement and
Engagement (PPIE) meetings to discuss research design
elements that would be acceptable to patients for a con-
dition that has been resistant to conventional medical
management. On 8 April 2016 a PPIE event was held at
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(BritSpine). At this event 7 patients and 22 professionals
attended a session to provide feedback and advice on
this application. On 24 July 2015 Guy’s & St Thomas’
Hospital hosted a PPIE meeting of participants from our
pilot study [16]. Eleven patients and their relatives
attended. In addition, another 10 patients attended a
subsequent meeting on 11 November 2016. The outline
of the proposed study was presented during both meet-
ings, where the patients were asked to enrol in the study
and to give their general thoughts on the study methods.
Two experienced facilitators from the local Research and
Design Service (RDS) fielded questions on recruitment,
comparison treatments, blinding, outcome measures and
methods and the dissemination of results. Feedback was
collected via assessment sheets, reviewed and incorpo-
rated into the study design. Patient and public engage-
ment meetings occur annually through the duration of
the study, with an additional dissemination meeting
scheduled for the final year.
During the PPIE Meetings a number of points were
raised:
1. The overall response to these meetings has been
thoroughly positive, and patients have expressed
their enthusiasm for this trial and willingness to
attend future meetings.
2. Patients described long-standing chronic pain, inad-
equate treatments and the need for long-lasting
therapy without medication.
3. Patients expressed a willingness to join the trial and
be allocated 50/50 to an active or inactive
treatment, with assurances being provided about
device activation at the end of the study.
4. Patients accepted the inclusion of a sham arm, but
we abandoned our original plan to cross over at 6
months and extend the trial to 12 months. We felt
that this approach would be unfair to patients who
were allocated active therapy that was then
withdrawn.
5. A 6-month blinded period was accepted as a rea-
sonable balance between patient and research
needs, but 12 months was too long.
6. Patients emphasized measures related to their
broader experiences, such as physical function,
disability and goal-orientated outcomes rather than
just pain.
7. Patient travel reimbursement maximums were
raised from £30 per visit to £50 per visit, as £30 was
deemed insufficient for patients travelling from
outside of London.
8. Throughout these meetings, the patients have an
appointed PPIE representative, Mr. Dean Walker.
Dean was a participant in our pilot study, joined theresearch team before this application was first
drafted and agreed to be a co-applicant. He has
attended all our PPIE events, has participated fully
as a member of the applicant team and will remain
on the research team until completion of the study.
Eligibility Criteria
The intended study population includes individuals with
CNLBP who have not had surgery. Participants will be
assessed for eligibility using the study-specific inclusion/
exclusion criteria during the screening visit.
Inclusion Criteria
Individuals are included according to the following
criteria:
1. 18-years old at the time of consent
2. Willing and able to sign and date the informed
consent form
3. Capable of independently comprehending and
consenting to the requirements of the study
4. Willing and able to comply with all study
procedures and study visits and available for the
duration of the study
5. Diagnosed with low back pain with VAS pain
scores ≥60 out of 100 mm for at least 12
consecutive months
6. Low back pain of greater intensity than any leg pain
7. Presence of clear component of neuropathic pain
based on a painDETECT Questionnaire score of
≥19 [24]
8. Degenerative disc disease confirmed by imaging or
internal disc degeneration as confirmed by
discography
9. Stable dose (no new, discontinuation of or change
in) of all prescribed pain medications for at least 4
weeks prior to screening and willing to maintain or
only decrease the dose of all prescribed pain
medications through Trial Assessment 2.
10. Has tried appropriate conventional medical
management for the pain
Exclusion Criteria
Individuals are excluded according to the following
criteria:
1. Presence of an active neurostimulator implanted
device, whether turned on or off
2. Previous spinal surgery
3. Current signs of a systemic infection
4. Pregnant or lactating, inadequate birth control, or
the possibility of pregnancy during the study
5. Current diagnosis of a progressive neurological
disease such as multiple sclerosis, chronic
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rapidly progressive arachnoiditis, rapidly progressive
diabetic peripheral neuropathy, brain or spinal cord
tumour, or severe/critical central or foraminal
spinal stenosis
6. Mechanical spine instability detected by a clinician
(validation by flexion/extension films of lumbar
spine in the past 12 months showing 4 mm or more
translational movement or excessive angular
movement manifested by > 5 degrees segmental
angular movement), e.g. any forms of
spondylolisthesis
7. A medical condition or pain in other area(s) that is
not the condition intended for treatment with SCS
and could interfere with the study procedures,
accurate pain reporting and/or confound evaluation
of the study endpoints, as determined by the
Investigator
8. Evidence of an active disruptive psychological or
psychiatric disorder or other known condition
significant enough to impact the perception of pain,
compliance of intervention and/or ability to
evaluate treatment outcome as determined by the
Investigator
9. Significant drug-related behavioural issues (e.g. al-
cohol dependency, illegal substance abuse)
10. Using greater than 120 mg morphine equivalents of
opioids daily
11. Structural abnormalities of the spine that may
prevent electrode implantation
12. Co-existing disorder of the nervous system that
may affect study measurements, e.g. polyneuropathy
13. Diagnosed with fibromyalgia or other generalised
pain syndromes
14. Active malignancy or diagnosis of cancer and not in
remission for at least 1 year prior to screening
15. Participating or planning to participate in another
clinical trial
16. Patient is in close contact with other people
involved with the study so that a high risk exists for
the patient to be unblinded.
Interventions
Removal of ‘Temporary Trial’ Phase from Design
A trial of stimulation is often performed in standard care
to eliminate non-responders prior to full implantation
This temporary trial of stimulation is performed by
implanting the leads and connecting them via a tempor-
ary extension to an external battery that the patient can
wear for up to 2 weeks. This is a recommendation of the
current NICE guidelines and the manufacturer’s device
manual.
RCT evidence does not support the role of temporary
screening trials for stimulation in predicting long-termoutcomes of the therapy [25]. Positive evidence exists of
harm from temporary screening trails, including higher
infection rates and the potential elimination of long-
term responders [26]. In our preliminary study on 10
kHz stimulation for patients with low back pain without
prior surgery, we noted a trial success rate of 95% [20].
This high success rate was credited to more stringent
patient selection, based on the characterisation of pain
mechanisms and other clearly defined inclusion criteria.
By removing the trial phase we reduce the number of
procedures that patients undergo from two to one.
Therefore, we assert that a pre-implantation trial of
10 kHz SCS in this population offers little clinical value
and, instead, increases the costs and harms; in the con-
text of the present trial, it would reduce the scientific
value of this research.
Identification and Description of the Investigational Device
The Senza™ System, a totally implantable SCS system
that is intended to aid in the management of chronic in-
tractable pain, received a European Union (EU) CE Mark
in May 2010.
The Senza System consists of a rechargeable implant-
able pulse generator (IPG) with 16 output channels. The
IPG is implanted in a subcutaneous pocket and is cap-
able of stimulating the spinal cord nerves when used
with one or two 8-contact percutaneous leads. The IPG
is controlled by a patient remote and/or a clinician
programmer.
Lead(s): The percutaneous lead has eight contacts.
Extension(s): An extension may be used during the
permanent implantation procedure, to connect the lead
to the IPG.
IPG: The IPG is a rechargeable stimulator with 16 out-
put terminals. Each of the 16 outputs can be programmed
as a cathode or an anode. The IPG is powered by a 3.6 V
nominal lithium-ion rechargeable battery. It is capable of
stimulating the spinal cord nerves through the electrodes
of the leads connected to any combination of the output
terminals, using one programmable current source.
Patient remote control: The patient remote control is
a handheld battery operated unit that the participant can
use to turn the stimulation on and off and to change the
stimulation programs/settings.
Charger: This charger is used to transcutaneously
charge the IPG battery. It is a portable device powered
by a rechargeable battery and can be held in one hand.
Clinician programmer: The clinician programmer is an
off-the-shelf laptop installed with proprietary software to
allow the programming of the IPG and participant re-
mote control.
Lead anchors: Lead anchors may be used to secure the
leads to the fascia, possibly preventing lead migration
and/or lead strain.
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groups; this involves four pairs of electrode groups
and each pair is switched on for 5 s before the next
pair is switched on (Fig. 2). Therefore, in 20 s, the
whole lead has been activated and the cycle repeats.
The rationale is that this avoids overstimulation, miti-
gates against small degrees of lead migration and
removes any need for reprogramming. During the
study, as both groups are programmed identically and
reprogramming is not expected, the risk is reduced
for unblinding and subsequent bias.
Device Implantation
Under standard operating theatre practice, all partici-
pants will be implanted with the following equipment:
10 kHz Senza IPG and two octopolar (8 contact) leads.
The first of the two leads will enter the epidural space
through a lumbar or lower thoracic epidural puncture.
The lead will be advanced cranially in the epidural space
to reach a final position, where contacts 4 and 5 span
the T9/10 disc space shown by Anterior-Posterior fluor-
oscopy in the anatomical midline as per our pilot experi-
ment (Fig. 2). A lateral image will be obtained to ensure
the lead is placed posteriorly in the epidural space.
Once satisfactory epidural lead placement is con-
firmed, the lead will be anchored to the deep fascia orFig. 2 Anterior-posterior X-ray position of desired lead location and diagrasupraspinous ligament and a strain relief loop will be
established. The active epidural lead will be tunnelled to
a subcutaneous pocket for the battery using an extension
if necessary. This subcutaneous pocket is made in the
gluteal region via a small skin incision and blunt sub-
cutaneous dissection. This pocket should be large
enough to accommodate the IPG, extensions and sham
lead. This active lead (AL) will be used to provide ther-
apy to the intervention group. The AL will be connected
to the first or top port of the IPG in all participants, and
a second sham lead (SL) will be inserted subcutaneously
and attached to the second port of the IPG (Fig. 3). Im-
pedances to check electrical integrity of the system will
be performed at this time. Information will be given
about wound care, and the device will remain ‘off’ until
the participant’s next visit. Removal of sutures (if neces-
sary) will be done at the implantation site.
Possibly, the SCS will need removal or repair. Reasons
for these actions include patient withdrawal from study,
infection, hardware failure, lead migration, SCS-related
pain, allergy or other adverse reaction to the device or
requirement for an MRI scan.
If this occurs, the participant must consent to a further
surgical procedure, which is a surgical process similar to
that of implantation. With removal, all hardware will be
removed, and with repair, the changes made to the SCSmmatic illustration of ‘cascade’
Fig. 3 Position of epidural lead (1), sham lead (2) and implantable Pulse Generator
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is unsatisfactory. The risk from these surgeries is
similar to that of implantation, with an additional
small risk that some of the components may not be
safely removed.
All such procedures will be done by the study
implanter.
Outcomes
Primary Outcome
The primary outcome is the comparison between the
intervention and the control of the effects of stimulation
delivered on the mean VAS back pain scores taken from
the 7 days of diary data from the week prior to and from
the 6 months following post-randomisation.Secondary Outcomes
The secondary outcomes include the following:
 A comparison of the secondary outcomes of
disability, depression, health-related quality of life,
patient’s global impression of change, sensation
maps and medication usage between intervention
and control at 1, 3, and 6 months post-
randomisation
 A comparison of the cost-effectiveness of 10 kHz
SCS between intervention and control at 6 months
post-randomisation
 A comparison between the intervention and control
of the complications and adverse events at 6 months
post-randomisation
Fig. 4 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) diagram
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Screening Visit
The schedule of events is listed in Fig. 4. Participants
will be given a copy of the patient information sheet and
informed consent form (Additional file 1); they will be
provided sufficient time to read and understand the
document and the opportunity to ask questions. Partici-
pants will be informed of their right to withdraw from
the study at any time without prejudice.
The screening visit will commence after each participant
has been enrolled. During the screening visit, the following
will be collected: eligibility assessment, participant demo-
graphics, medical history, pain map, pain severity on a 0-
100mm (VAS), painDETECT questionnaire, pregnancy
test from all female participants of child-bearing potential,
and pain medication usage.
If a participant reports a painDETECT score lower than
19, they will be discontinued from the study. During the
screening visit, participants will be provided with a multi-
day diary. Participants will record their VAS back and leg
pain scores for 7 days prior to the baseline visit.
Baseline Visit
During the Baseline visit, participants will be asked to
complete the following questionnaires after being pro-
vided detailed instructions: the Oswestry Disability
Index (ODI v2.1a), Patient Health Questionnaire
(PHQ-9), Pittsburgh Sleep Quality Index (PSQI), EQ-5D-5 L, pain medication usage, work status and work
absence. If a participant reports a mean VAS back pain
score lower than 60 mm on their multi-day pain diary,
they should be discontinued from the study.Randomisation and Device Activation
The randomisation and device activation visit will take
place between 2 and 4 weeks post-implantation, pending
proper wound healing.
Firstly, the following will be performed by blinded
study personnel:
 Participants will be assessed to determine whether
they have experienced any adverse events, and a case
report form (CRF) will be completed, as applicable.
 New x-ray images will be taken to record the lead
locations.
 Participants will be provided with a multi-day diary
and instruct to record their VAS pain scores daily
for 7 days prior to the 1-month follow-up.
 The participant’s device and lead will be programmed
according to their allocated group; whereas the lead is
different, the programming parameters used are
identical and can be found in Fig. 2.
At this point, the participant enters the ‘follow-up’
phase of the study, with visits at 1, 3 and 6months.
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routine clinical practice.
During these visits, all participants will be asked to
complete the following questionnaires in addition to
bringing their multi-day pain diary:
 Pain severity on a 0-100 mm (VAS)
 Pain map
 Oswestry Disability Index (ODI v2.1a)
 Patient Health Questionnaire 9 (PHQ-9)
 Pittsburgh Sleep Quality Index (PSQI)
 EQ.5D-5 L
 Pain medication usage
 Patient Global Impression of Change (PGIC)
 Participant satisfaction
 Sensation map.
Any adverse events are monitored and documented in
the CRF. An X-ray may be taken if there are any con-
cerns about lead migration.
To check fidelity of blinding, participants and assessors
will be asked to guess their treatment allocation at the
end of the study. We will monitor potential outcome as-
sessor blinding by asking them to guess each patient’s al-
location at the end of each follow-up assessment. After
the trial is completed, we will compare actual and antici-
pated treatment allocations.
After 6-month Follow-up
After the 6-month visit all patients will be managed in
the standard pain management service, outside the trial.
Medication Usage
All medications prescribed for the treatment of pain will
be recorded during the screening visit. Only participants
who are on a stable dose of all prescribed pain medica-
tions for at least 4 weeks prior to screening and willing
to maintain or decrease the dose of all prescribed pain
medications are eligible for participation in this study.
Any changes to an enrolled participant’s pain medica-
tions during the study will be recorded.
The addition of pain medications for the relief of surgi-
cal discomfort after implant procedures is allowed. Pain
medications prescribed for short-term post-operative pain
management are not considered an increase in pain medi-
cations if the medication is ceased and the medication end
date is prior to the date of randomisation.
All medications used to treat adverse events (regard-
less of the reason prescribed) will be documented as in-
terventions on the Event CRF.
Sample Size
For our primary outcome of pain severity VAS (0-100
mm), the Initiative on Methods, Measurement and PainAssessment in Clinical Trials (IMMPACT) proposes a
minimally important clinical difference (MICD) of 20
mm [27]. To detect this MICD and based on a back/leg
pain VAS standard deviation of 25 mm, as seen in previ-
ous conventional and 10Khz-SCS RCTs set at 90%
power and 5% alpha, and a worst case attrition rate of
30% at 6-months follow up, we will need to recruit 96
participants (48 per centre) per group.
Recruitment
Recruitment will be from outpatients of the two cen-
tres. The study will be presented in national and
international meetings to a target audience of pain
physicians, spinal surgeons, neurosurgeons and phys-
iotherapists. Advertising will be conducted through
newspapers and magazines to enhance recruitment.
Road shows were organised to target spine surgeons,
neurosurgeons and pain physicians.
Assignment of Intervention
Allocation: Sequence Generation
Patients will be randomised using a validated and password-
protected trial website, designed and supported by UK CRC
registered Exeter Clinical trials unit (CTU).
Allocation Concealment
Patients will be allocated 1:1 to intervention or control
and were stratified by centre using a web-based
computer-generated random-allocation sequence to en-
sure concealment. This website will be password pro-
tected and managed by Exeter CTU.
Blinding
Patients, investigators, outcome assessors and analysts
will all be blinded. Only two study nurses at each site
will be unblinded to the treatment received by the
participants.
Data Collection/Management
Data analyses will be conducted and reported in accord
with CONSORT (Consolidated Standards Of Reporting
Trials) guidelines for non-drug trials [28]. Participant
flow will be summarised using a flow diagram, which
will report recruitment and drop-outs and baseline pa-
tient characteristics and outcome scores reported and
compared by group. The primary analysis for the pri-
mary and secondary outcomes will take an intention-
to-treat approach based on a between-group compari-
son of intervention and control participants with
complete data at 6 months, with adjustments being
made for the baseline outcome score and centre. In a
secondary analysis we will extend the primary analysis
model with a repeated measures comparison of groups
at all follow-up points. We comprehensively examine
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undertake appropriate imputation models to assess the
impact of missingness on primary analysis models. Re-
sults will be reported for between-group mean differ-
ences and 95% confidence intervals. Safety outcomes
will be reported descriptively by group. No correction
of P values for multiplicity of testing will be under-
taken. However, the primary outcome analysis will be
performed before all other analyses, and the P values of
all subsequent analyses will be interpreted in the con-
text of multiple testing. No interim analyses are
planned.
Economic Evaluation Methods
The economic evaluation aims to estimate the cost-
effectiveness of 10 kHz SCS plus usual medical care
when compared to sham stimulation plus usual medical
care. Healthcare resource utilisation, e.g. management of
adverse events, interventions, investigations, medication,
inpatient hospitalisations, Emergency Department and
other health-care related visits, plus out-of-pocket costs
and absences from work will be collected for each pa-
tient during the study follow-up period. Resources re-
quired for the implantation intervention will be recorded
within the trial.
Items of resource use will be costed using national av-
erages obtained from national sources (such as the Per-
sonal Social Services Research Unit, the British National
Formulary and National Health Service (NHS) reference
cost databases). Cost components will be combined to
derive total patient level costs for the NHS. In addition,
non-NHS costs such as productivity loss due to absence
from work or patient out-of-pocket expenses will also be
quantified to provide a full picture of how the strategies
being compared will affect the financial burden imposed
by the condition on both the NHS and the patients.
Generic health-related quality-of-life (HRQoL) data
will be collected using the EQ-5D-5 L instrument. Both
resource utilisation (costs) and EQ-5D-5 L will be col-
lected at each follow-up visit. A within-trial cost conse-
quence analysis will be carried out to estimate mean
resource utilisation, costs, EQ-5D scores and total
quality-adjusted life years (QALYs) in each group, to-
gether with relevant measures of sampling uncertainty.
QALYs will be calculated using the area under the curve
approach, with regression-based adjustment for the
baseline EQ-5D score.
The economic evaluation will take the form of a cost-
utility analysis to calculate the cost per additional QALY
gained. Base-case analyses will be conducted from the
NHS perspective, with additional analyses being con-
ducted from the societal perspective. Deterministic and
probabilistic sensitivity analysis will be undertaken to ex-
plore the robustness of the results to plausible variationsin key assumptions and variations in the analytical
methods used. Cost-effectiveness acceptability curves
will be constructed to show the probability that the
intervention is cost-effective at specific thresholds of
cost per QALY gained. The analyst will be blinded to
the group allocation.
Statistical Methods
The trial statistician will be blinded to the group alloca-
tion and will undertake analyses using STATA. A de-
tailed statistical analysis plan (SAP) will be prepared that
will be presented to the Trial Steering Committee (TSC)
and Data Monitoring Committee (DMC) for their review
ahead of any analysis being undertaken.
Data Monitoring
A joint Trial Steering Committee (TSC) and Data Moni-
toring Committee (DMC) will provide supervision for the
trial, providing advice to the Chief and Co-investigators
(Trial Management group [TMG]) on all aspects of the
trial conduct and affording protection for patients by en-
suring the trial is conducted according to the Medical Re-
search Council (MRC) Guidelines for Good Clinical
Practice in Clinical Trials. The TSC/DMC will be chaired
by an academic clinician independent of the trial plus
three other members plus the chief investigator, trial man-
ager, statistician and health economist.
Harms
Foreseeable Adverse Events and Anticipated Adverse Device
Effects
We expect the risk of serious adverse events to be rare,
and our results from the previous 10 kHz stimulation
trial showed the risk of adverse events to be as follows:
 Battery pocket pain 8%
 Wound infection 3%
 Electrode migration 5%
 Lead Fracture or malfunction 6%
 Headache from epidural puncture 1%
 Nerve injury < 1%
 Spinal cord haematoma and abscess < 1%
 Unwanted, perceived stimulation < 1%
Pocket pain is usually self-limiting within 6 months,
and electrode migration is mitigated using cascade
stimulation programming. Wound infection will necessi-
tate the removal of the device. In some instances the sys-
tem will require repair or removal. The reasons for this
include infection, hardware displacement, pain or dis-
comfort from the device, or device failure. The risks are
similar to those mentioned above.
All adverse events will be recorded and reported in ac-
cordance with Good Clinical Practice.
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Possibly, the SCS will need to be removed or repaired.
Reasons include patient withdrawal from study, infec-
tion, hardware failure, lead migration, SCS related pain,
allergy or other adverse reaction to device, or a required
MRI scan.
If this occurs, the participant must consent to a further
surgical procedure, and the surgical process is similar to
that of implantation. With removal, all hardware will be
removed, and with repair, the changes necessary to the
SCS components will be determined by which compo-
nent is unsatisfactory. The risk from these surgeries is
similar to that of implantation, with a small risk that
some of the components may not be safely removed. All
such procedures will be done by the study implanter.
Any adverse events are monitored and documented in
the CRF.Auditing
The TSC will meet three times in the first year, twice in
the second year and three times during the third year.
The DMC will meet twice in the first year and annually
thereafter.
If the chief and co-investigators are unable to resolve
any concern satisfactorily, personal investigators, and all
others associated with the study, may write to the chair-
person of the TSC, through the trial office, drawing at-
tention to any concerns they may have about the
possibility of particular side-effects or about any other
matters thought relevant. Interim analyses of recruit-
ment rate, safety and outcome data will be supplied, in
strict confidence, to the committee, along with any other
analyses that the committee may request.Ethics and Dissemination
Declaration of Helsinki, International Standards and
National Regulations
The clinical investigation shall be conducted in accordance
with the ethical principles of the Declaration of Helsinki, ISO
14155, and all other applicable device and UK regulations.
Central ethical approval was provided by London-
Camberwell St. Giles Research Ethics Committee for both
centres, part of the NHS Health Research Authority. REC
reference: 18/LO/1031, IRAS project ID: 232729. We will
not begin recruiting at other centres in the trial until local
ethical approval has been obtained. Informed written con-
sent will be obtained prior to trial participation.Protocol Amendments
Any protocol amendments will be discussed and ap-
proved within the TMG and presented to inform the
TSC/DMC.Consent
The principal investigator or qualified designee will
document the informed consent process, including the
date of consent and name of the person conducting
the consent process in the participant’s medical rec-
ord. Individuals will be considered enrolled in the
study once they have signed the informed consent
form (Additional file 1). On the consent form, partici-
pants will be asked if they agree to the use of their
data by responsible and designated individuals in the
Foundation trust and regulatory authorities, the Exeter
CTU and other collaborators. Participants will also be
asked for permission to be contacted about future re-
search projects, where relevant. This trial does not in-
volve collecting biological specimens for storage.Confidentiality
All data will be handled in accordance with the UK Data
Protection Act 1998. The CRFs will not bear the participant’s
name or other personal identifiable data. The participant’s
initials, date of birth and trial identification number will be
used for identification. Participants will be assigned a trial
identification number by the study site sequentially upon en-
rolment into the study. The study site will maintain a master
participant identification log.Dissemination
The results of this trial will be reported and presented at
national and international meetings. The outcomes will
be published in high-quality, peer-reviewed journals to
make the results available to other physicians and scien-
tists. Further long-term outcomes will be reported to po-
tentially validate the longevity of the therapy.Discussion
The results of this study will demonstrate whether the
application of 10Khz-SCS in patients with CNLBP is a
suitable alternative to conventional medical therapy.
Multiple large-scale trials involving the use of SCS thus
far have been industry-sponsored without the use of a
placebo group. Many studies have chosen not to use a
placebo arm with a high probability of unblinding due to
the nature of SCS. The methods used in this trial at-
tempt to ensure that unblinding does not take place.
The sham lead positioned outside the epidural space en-
sures energy consumption without neurostimulation, re-
quiring the patient to recharge the device. None of these
participants will have had exposure to SCS prior to the
trial, so the experience of the therapy will be novel. As
this is the first trial to apply these concepts, the results
will act as a support for future trials evaluating the effi-
cacy of SCS in other pathologies.
Al-Kaisy et al. Trials          (2020) 21:111 Page 12 of 13Trial Status
The current protocol version is V1.2 dated 18 December
2018. The start date of the study was 14 August 2018,
and patients are currently being recruited. Recruitment
is expected to be completed by 1 December 2020. The
estimated primary completion date is 1 July 2021.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3831-4.
Additional file 1: Consent form.
Additional file 2: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents*.
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